Continue Reading With Our 7-Day Free Trial
By a margin of one vote — 215 to 214 — the U.S. House of Representatives passed the “One Big Beautiful Bill Act” on May 22, the most sweeping fiscal legislation since the 2017 Tax Cuts and Jobs Act. The bill permanently extends those tax cuts, accelerates depreciation for businesses, repeals the Biden-era methane tax, slashes Medicaid and SNAP, and accelerates the phase-out of clean energy tax credits. The Congressional Budget Office estimates the bill adds $4.1 trillion to the deficit over the next decade, including $700 billion in added interest costs alone — arriving on top of a bond market where the 30-year Treasury yield had already hit near two-decade highs this week.
The initial market reaction was constructive. U.S. equities moved higher, Treasury yields ticked up further, and the U.S. dollar strengthened — largely reflecting the removal of uncertainty around U.S. taxation and spending rather than a genuine embrace of the fiscal arithmetic. The energy sector and mid-cap industrials saw immediate tailwinds. Healthcare and clean energy names took immediate hits.
But the first-order reaction tells only part of the story. The bill reshapes earnings models, sector cost structures, and capital allocation decisions in ways that will compound Over the Next 12 to 24 Months across companies with very different exposure to each provision.
What Moved, What Didn’t, & Why The Gap Is The Story
Energy names moved first and fastest. The methane tax repeal and the unlocking of federal lands for oil and gas development are direct, near-term margin tailwinds for integrated majors and exploration producers. The energy sector has already been the best-performing in the S&P 500 in 2026, up roughly 25% versus the broader index’s 8% gain year-to-date — and the bill adds a structural policy tailwind to what has already been a strong fundamental cycle.
Clean energy names moved sharply in the other direction. Enphase Energy (NASDAQ: ENPH) dropped 5.1% on the session, NextEra Energy (NYSE: NEE) fell 3.8%, Sunrun (NASDAQ: RUN) plunged close to 10%, and AES Corporation (NYSE: AES) shed more than 4%. These moves are directionally correct but are likely still undersizing the structural damage to these companies’ multi-year earnings models, particularly for residential solar names.
Healthcare stocks repriced more quietly — but the mechanism there is if anything more structurally damaging than the clean energy selloff, and several key names have not yet moved enough given what the Medicaid cuts imply for their membership enrollment, per-member revenue, and long-term growth outlook in a market that was already stressed.
Energy: The Bill’s Clearest Corporate Beneficiary
ExxonMobil (NYSE: XOM) and Chevron (NYSE: CVX) are the most direct beneficiaries among large-cap names. The repeal of the Biden-era methane tax removes a direct operating cost that had been weighing on upstream margin assumptions. The unlocking of federal lands for oil and gas development expands the addressable drilling inventory for both companies at no incremental capital cost — the leases simply become available under more favorable terms.
ExxonMobil is guiding for $27 to $29 billion in capital expenditures for 2026 and has $20 billion in share repurchases planned — a capital allocation posture that assumes structurally elevated oil prices. Chevron returned $27.1 billion to shareholders in 2025 and carries a lower breakeven structure than Exxon, giving it more earnings resilience in a soft oil environment. The policy windfall from the bill does not change the commodity price outlook, but it lowers the cost floor for domestic production and extends the runway on the companies’ federal land drilling programs — a meaningful margin tailwind for upstream-heavy segments at both majors.
The accelerated depreciation provisions also benefit the broader energy sector’s capital-intensive project pipeline. For independent producers with large domestic drilling programs, the reduction in effective corporate tax rates — from the statutory 21% down to roughly 14–15% for median firms — improves the economics of projects that were marginally accretive under the prior tax structure.
Healthcare: The Medicaid Mechanism the Market Is Underpricing
UnitedHealth Group (NYSE: UNH) entered 2026 already under severe pressure. The company had warned investors of its first annual revenue decline in more than three decades, projecting revenue of “greater than” $439 billion for 2026 — roughly a 2% drop from the prior year and well below the analyst consensus of $454 billion. The stock fell nearly 20% in January on that guidance. The OBBBA compounds an already deteriorating situation: the bill tightens Medicaid eligibility, restricts ACA Marketplace enrollment, and cuts Medicaid financing in ways that shrink and destabilize the exact public-coverage pools in which UnitedHealth participates.
Humana (NYSE: HUM) faces structurally similar exposure through its Medicare Advantage business and its significant Medicaid managed care book. The broader mechanism is straightforward: fewer Medicaid-eligible members means lower per-member revenue, higher medical loss ratios as the remaining insured pool skews sicker, and increasing pressure from state budget adjustments that typically follow federal Medicaid funding cuts. Neither company can easily offset the membership volume decline through pricing — government-rate contracts are set by CMS, not negotiated. The margin compression from Medicaid cuts is not a one-quarter event; it plays out over multiple enrollment cycles.
Clean Energy: Which Names Are Structurally Broken & Which Are Not
The bill accelerates the phase-out of the Investment Tax Credit and Production Tax Credit for wind and solar, requires projects to begin construction by 2026 to retain the 30% credit, and ends the 25D residential solar credit that had been the primary consumer incentive driving rooftop installations. For the residential solar segment, this is a direct demand destruction mechanism.
Sunrun (NASDAQ: RUN) is the most structurally exposed name. Its entire model depends on consumer willingness to adopt residential solar, and the 25D credit had been a primary conversion driver. Without it, the third-party ownership model becomes harder to finance and harder to sell to consumers who lack sufficient tax liability to benefit from the credit anyway. KeyBanc Capital Markets slashed its rating on Sunrun to Underweight in the wake of the bill’s Senate draft, warning that the new legislation may fundamentally challenge its business model.
First Solar (NASDAQ: FSLR) is a materially different case. As the only major solar panel manufacturer that is both U.S.-headquartered and manufactures exclusively in the U.S. and allied nations, First Solar is insulated from the tariff storm hitting Chinese-dependent competitors and continues to receive manufacturing tax credits under Section 45X. The company entered 2026 with a backlog of 54.5 GW. While the OBBBA curtails the ITC and PTC that its utility-scale customers rely on, and the Senate version includes provisions that could affect Section 45X credit stacking, First Solar’s domestic production advantage gives it a structural buffer that Sunrun, Enphase, and other residential or import-dependent names simply do not have.
Enphase Energy (NASDAQ: ENPH), while operationally strong — with gross margins of 54% and Q4 2025 EPS of $0.71, beating estimates of $0.58 — faces direct headwinds from the residential credit expiration. Its high-beta status in U.S. residential solar sentiment means the policy shift hits valuation before it hits earnings, and then hits earnings as installation volumes soften through 2026 and into 2027.
NextEra & The Utility Sector: Two Problems Colliding
NextEra Energy (NYSE: NEE) sits at the intersection of two simultaneous headwinds from this legislation. As the largest U.S. utility by market cap and a major wind and solar developer, it faces the clean energy credit phase-out directly in its renewable development pipeline. But it also faces the bond market channel: Treasury yields moving higher on fiscal concerns directly compress utility valuations, as investors benchmark dividend yields against risk-free rates. NextEra’s stock has already fallen roughly 4% on the day’s session.
The mechanism on the clean energy side is specific. Projects that don’t break ground before the 2026 deadline lose access to the 30% ITC and PTC structures that underpin their financial models. NextEra’s development pipeline extends years into the future — and a significant portion of those planned projects were underwritten with the assumption that these credits would remain intact. The repricing of that pipeline, combined with a higher cost of capital from rising Treasury yields, is a compounding double-impact that the single-day stock reaction has not fully absorbed.
The Names That Have Not Moved Enough
HCA Healthcare (NYSE: HCA) is the name most likely to see delayed but significant repricing. Hospitals are the direct backstop when Medicaid cuts result in higher uninsured patient volumes. The American Hospital Association has warned publicly that the OBBBA will cause millions to lose marketplace coverage and become uninsured — and that uninsured population shows up in hospital emergency rooms, where care is delivered but not compensated at commercial rates. HCA’s exposure is disproportionately concentrated in markets with large Medicaid populations, making the earnings impact more acute than the current stock movement suggests.
Molina Healthcare (NYSE: MOH) is even more directly exposed. Unlike UnitedHealth or Humana, which have diversified commercial and Medicare businesses that partially buffer Medicaid headwinds, Molina’s entire book is concentrated in Medicaid and Marketplace coverage — the two pools the OBBBA hits most directly. The stock has not repriced to the same degree as UNH, creating a potential asymmetric risk over the next two to four quarters as enrollment data arrives.
Over the next 12 to 18 months, the companies most likely to see meaningful downward revisions to consensus estimates are those with heavy Medicaid membership exposure, large unhedged residential solar pipelines, and utility-scale renewable development programs underwritten against pre-OBBBA credit assumptions. The energy sector beneficiaries are more likely to see the policy tailwind show up in capital allocation announcements — expanded drilling programs, buyback acceleration — than in immediate earnings beats.
Long-Term Structural Implications
The OBBBA represents a generational shift in the fiscal trajectory of U.S. sovereign borrowing. With the U.S. fiscal deficit already running at 6.2% of GDP in 2025 and net interest expenditure consuming 3.1% of GDP — near the early 1990s peak — an additional $4.1 trillion in projected deficit over the next decade arrives as a structural, not cyclical, supply driver for the Treasury market. Bond traders have already pushed yields toward near two-decade highs this week. The bill adds permanent fiscal fuel to that fire.
For corporate capital allocation, the accelerated depreciation provision is potentially the most durable positive signal. Reducing the effective tax rate from 21% to 14–15% for the median firm improves the after-tax return on almost every capital project and gives boards a cleaner argument for expanding domestic capex. Small and mid-cap manufacturers and industrials are the primary beneficiaries in this analysis — companies with large domestic fixed asset bases that depreciate rapidly. The M&A and IPO pipeline may also benefit from improved after-tax cash flows and reduced policy uncertainty.
The clean energy transition, however, faces a structural reset. The IRA’s framework — which had attracted hundreds of billions in committed private investment — is now materially curtailed. Developers who were mid-planning-cycle on projects that needed credits to pencil out will face difficult decisions about whether to accelerate into 2026 timelines or abandon projects entirely. That binary will be visible in project announcement data by late 2026.
Final Thoughts: A Bill With Sharply Divergent Impact Across Named Companies
The “One Big Beautiful Bill” is not a monolithic market event. It creates meaningful earnings tailwinds for ExxonMobil and Chevron, a prolonged margin headwind for UnitedHealth and Humana, an existential model challenge for Sunrun, and a structural buffer opportunity for First Solar relative to its solar peers. The bond market channel — higher yields compounding the fiscal deficit narrative — adds pressure to NextEra and the utility sector from a direction entirely separate from the clean energy credit phase-out.
The stocks that moved on the day captured the first-order sector rotation. The second-order repricing — in hospital systems like HCA, in Medicaid-concentrated managed care names like Molina, and in utility-scale renewable developers who hadn’t yet hit the construction threshold — is still working through. Monitoring Q2 enrollment data for managed care names, project backlog announcements from renewable developers, and the Senate reconciliation process — which is expected to revise the bill further before final passage — will be more informative than reacting to today’s single-session moves.
Disclaimer: We do not hold any positions in the above stock(s). Read our full disclaimer here.
